Biomedical Research

Objective: SAR1B, apoB and MTTP were involved in lipid metabolism, which is important for the development of ICAS. This study aimed to investigate the expression of SAR1B, apoB and MTTP in patients with intracranial atherosclerotic stenosis (ICAS) and the clinical significance.

Methods: Eighty patients with acute ischemic stroke were selected in our hospital from Jan 2016-Jun 2016. According to the results of imaging examinations and other clinical data, patients were divided into ICAS group (n=32), Extracranial Atherosclerotic Stenosis (ECAS) group (n=20) and No Atherosclerotic Stenosis (NCAS) group (n=28). LDL-C and HDL-C levels were detected by selective inhibition method and immunization inhibits method respectively, level of ApoB was determined by immunofluorescence, levels of SAR1B and MTTP were detected by Enzyme-Linked Immunosorbent Assay (ELISA).

Results: Compared with NCAS group, LDL-C level was increased and HDL-C level was decreased in ICAS group, while no significant difference were found between ECAS and NCAS groups; apoB and SAR1B levels were higher in ICAS group than in NCAS group, no significant differences were found between ECAS and NCAS groups, in addition, there were no significant differences in MTTP level between groups; serum SAR1B and apoB levels were positively correlated with the level of serum LDLC level; SAR1B and apoB levels were positively correlated with the MRA diagnostic score of patients with ICAS.

Conclusion: Expression levels of SAR1B and apoB were specifically increased in ICAS patients, so the increased expression levels of SAR1B and apoB can be used as biomarkers for diagnosis of ICAS.

Author(s): Hu Jun, Xu Xiaonan, Chen Xuhui, Lin Kaihua, Huang Zhenyi, Wu Jun
Abstract | Full-Text | PDF

Share this